

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 8917

SERIAL NUMBER	FILING or 371(c)	CLASS	GROUP ART	UNIT	ATTO	RNEY DOCKET				
10/580,962	DATE 05/31/2006	514	1617			NO. 29248/29				
	RULE				l					
APPLICANTS	APPLICANTS									
Erik Buntinx, Alken, BELGIUM;										
** CONTINUING DATA **********************************										
This application is a 371 of PCT/BE04/00172 12/02/2004 which is a CON of 10/725,965 12/02/2003										
and is a CON of 10/752,423 01/06/2004										
which is a CIP of 10/725,965 12/02/2003 and said PCT/BE04/00172 12/02/2004										
is a CON of 10/803,793 03/18/2004										
which is a CIP of 10/752,423 01/06/2004 which is a CIP of 10/725,965 12/02/2003										
and said PCT/BE04/00172 12/02/2004										
is a CON of 10/984,683 11/09/2004										
which is a CIP of 10/803,793 03/18/2004 which is a CIP of 10/752,423 01/06/2004										
which is a CIP of 10/725,965 12/02/2003										
** FOREIGN APPLICATIONS ************************************										
CANADA 2451798 12/02/2003 EUROPEAN PATENT OFFICE (EPO) 03447279.5 12/02/2003										
EUROPEAN PA	ATENT OFFICE (EPO) (04447001.1 01/05/2004	ļ							
EUROPEAN PATENT OFFICE (EPO) 04447066.4 03/18/2004 CANADA 2461248 03/18/2004										
EUROPEAN PATENT OFFICE (EPO) 04025035.9 10/21/2004										
JAPAN 2004-349085 11/04/2004 CANADA 2487529 11/15/2004										
** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** ** SMALL ENTITY **										
12/28/2006										
Foreign Priority claimed	Yes No No Met a	STATE OR	SHEETS	TOTA		INDEPENDENT				
35 USC 119(a-d) conditions me Verified and /SARAH F	PIHONAK/		DRAWINGS	CLAII		CLAIMS				
Acknowledged Examiner's		BELGIUM	15	28	<u>'</u>	3				
ADDRESS										
AMSTER, ROTHSTEIN & EBENSTEIN LLP 90 PARK AVENUE										
NEW YORK, NY 10016										
UNITED STATES										
TITLE Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists										
Use of 04 and 5	-nt2a antagonists, inver	se agonists or partial ac	<u> </u>							
			☐ All Fe	es						
☐ 1.16 Fees (Filing)										

I DECENTED	FEES: Authority has been given in Paper No. to charge/credit DEPOSIT ACCOUNT		☐ 1.17 Fees (Processing Ext. of time)		
1150	No	for following:	☐ 1.18 Fees (Issue)		
			Other		
			☐ Credit		